Orser Capital Management LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 25,675 shares of the medical research company's stock, valued at approximately $2,323,000. Edwards Lifesciences comprises approximately 1.2% of Orser Capital Management LLC's investment portfolio, making the stock its 25th largest holding.
Several other institutional investors and hedge funds have also bought and sold shares of EW. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the third quarter worth $25,000. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the 1st quarter valued at $25,000. MV Capital Management Inc. purchased a new position in Edwards Lifesciences during the 4th quarter valued at $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences in the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth $27,000. Hedge funds and other institutional investors own 79.46% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on EW shares. BTIG Research raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Tuesday, June 30th. Leerink Partners raised shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Mizuho lifted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Finally, Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a "neutral" rating in a report on Friday, April 24th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.27.
Get Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Stock Up 0.4%
EW stock opened at $89.33 on Friday. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $51.44 billion, a PE ratio of 51.34, a price-to-earnings-growth ratio of 2.23 and a beta of 0.85. The business has a 50 day moving average of $88.13 and a 200 day moving average of $84.04.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the company posted $0.67 earnings per share. The company's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Insider Transactions at Edwards Lifesciences
In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the firm's stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company's stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 43,539 shares of company stock valued at $3,685,364 in the last quarter. 0.31% of the stock is owned by insiders.
About Edwards Lifesciences
(
Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
